Perrigo Reports $1.3B Goodwill Impairment and Cuts FY2026 EPS Outlook
PRGO is trading near its 52-week low of $12.17 (12% above the low).
Summary
Perrigo Company plc announced a significant $1.3 billion goodwill impairment charge for Q4 2025 and issued a substantially reduced adjusted EPS outlook for fiscal year 2026, alongside plans for a 7% workforce reduction.
Key Events · Earnings and Guidance · PRGO
-
Goodwill Impairment
Perrigo recognized a $1.3 billion goodwill impairment charge in Q4 2025, primarily due to a sustained decrease in share price and lower expected cash flows, particularly from its infant formula business. An additional non-cash goodwill impairment of up to $350 million may be recorded in Q1 2026.
-
Q4 2025 Adjusted EPS Miss
Adjusted diluted EPS for Q4 2025 was $0.77, a decrease from $0.93 in the prior year, reflecting lower gross profit in infant formula and soft OTC category consumption.
-
FY 2026 Adjusted EPS Outlook Cut
The company issued an FY2026 'All In' adjusted diluted EPS outlook of $2.00 to $2.30, a significant reduction compared to the $2.75 adjusted EPS reported for FY2025.
-
Workforce Reduction & Cost Savings
Perrigo launched a new operational enhancement program, expecting to reduce its workforce by approximately 7% and achieve $80 million to $100 million in annualized pre-tax cost savings by the end of FY2027.
Analysis · PRGO · Life Sciences
The filing reveals a challenging financial picture for Perrigo, highlighted by a massive $1.3 billion goodwill impairment charge in Q4 2025, which significantly impacted reported earnings. This impairment, coupled with a substantial reduction in the fiscal year 2026 adjusted EPS outlook (from $2.75 in FY2025 to $2.00-$2.30), signals significant headwinds and a re-evaluation of the company's asset values and future profitability. The company's plan to reduce its workforce by approximately 7% as part of a new operational enhancement program, while aimed at cost savings, underscores the need for aggressive restructuring in response to "near-term industry pressures" and "soft consumer consumption." Investors should be concerned about the magnitude of the impairment and the lowered guidance, which suggest a difficult transition year ahead for the company.
At the time of this filing, PRGO was trading at $13.60 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $12.17 to $30.93. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.